Silviu Itescu - CEO - Mesoblast (ASX:MSB) is using its proprietary mesenchymal lineage cell technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
Silviu Itescu – CEO – Mesoblast (ASX:MSB) is using its proprietary mesenchymal lineage cell technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
Post Views:283
Serving up fresh finance news, marker movers & expertise.
